Steve Schonfeld’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-382,233
Closed -$50.4M 2716
2025
Q1
$50.4M Buy
382,233
+361,693
+1,761% +$45.1M 0.3% 35
2024
Q4
$1.72M Sell
20,540
-197
-0.9% -$16.2K 0.01% 892
2024
Q3
$1.52M Sell
20,737
-113,717
-85% -$8.55M 0.01% 1009
2024
Q2
$9.21M Buy
134,454
+110,036
+451% +$7.63M 0.06% 371
2024
Q1
$1.69M Sell
24,418
-141,703
-85% -$9.74M 0.01% 1050
2023
Q4
$11.9M Buy
+166,121
New +$9.56M 0.08% 300
2022
Q4
Sell
-32,071
Closed -$1.49M 3084
2022
Q3
$1.49M Sell
32,071
-31,130
-49% -$1.63M 0.01% 1025
2022
Q2
$3.61M Sell
63,201
-34,724
-35% -$1.97M 0.04% 561
2022
Q1
$5.99M Buy
97,925
+76,210
+351% +$3.96M 0.05% 391
2021
Q4
$1.14M Buy
+21,715
New +$912K 0.01% 874
2017
Q4
Sell
-131,980
Closed -$2.08M 911
2017
Q3
$2.08M Buy
+131,980
New +$1.94M 0.19% 154
2017
Q2
Sell
-30,989
Closed -$504K 803
2017
Q1
$504K Buy
+30,989
New +$448K 0.05% 365
2016
Q3
Sell
-11,871
Closed -$460K 573
2016
Q2
$460K Buy
+11,871
New +$427K 0.1% 240

Other funds holding ITCI

Steve Schonfeld's ITCI Position: Q2 2025 in Review

Steve Schonfeld sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 382,233 shares — an estimated $50.4M sold.

Steve Schonfeld first reported a position in ITCI in Q2 2016 and held it in 13 quarters. The position peaked at $50.4M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Steve Schonfeld reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 382,233 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $50.4M.
  • Steve Schonfeld first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 13 quarters.
  • Steve Schonfeld's Intra-Cellular Therapies Inc. position peaked at $50.4M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.